bioAffinity Technologies (BIAF) Stock Price, News & Analysis

Company Overview

bioAffinity Technologies, Inc., a biotechnology company, engages in developing non-invasive diagnostic tests and targeted cancer therapeutics. The company offers CyPath lung, a diagnostic test, for early detection of lung cancer. It also researches targeted therapies to treat lung cancer and other diseases of the lung at the cellular level. The company was incorporated in 2014 and is based in San Antonio, Texas.

Key Stats

• Today's Range: $0.24 to $0.27
• 50-Day Range: $0.23 to $0.37
• 52-Week Range: $0.16 to $2.26
• Volume: 224,603 shs
• Average Volume: 553,682 shs
• Market Capitalization: $7.22 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Hold

BIAF Stock Analysis - Frequently Asked Questions

How have BIAF shares performed this year?

bioAffinity Technologies' stock was trading at $0.91 at the beginning of the year. Since then, BIAF shares have decreased by 72.1% and is now trading at $0.2536.

How were bioAffinity Technologies' earnings last quarter?

bioAffinity Technologies, Inc. (NASDAQ:BIAF) issued its quarterly earnings data on Thursday, August, 14th. The company reported ($0.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by $0.03. The business earned $1.27 million during the quarter, compared to analyst estimates of $1.51 million. bioAffinity Technologies had a negative trailing twelve-month return on equity of 845.68% and a negative net margin of 152.16%.

When did bioAffinity Technologies IPO?

bioAffinity Technologies (BIAF) raised $8 million in an initial public offering on Thursday, September 1st 2022. The company issued 1,300,000 shares at $6.00-$6.25 per share. WallachBeth Capital served as the underwriter for the IPO and Craft Capital Management was co-manager.

How do I buy shares of bioAffinity Technologies?

Shares of BIAF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of bioAffinity Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that bioAffinity Technologies investors own include Lowe's Companies (LOW), Meta Platforms (META), Costco Wholesale (COST), Intel (INTC), AIM ImmunoTech (AIM), Alnylam Pharmaceuticals (ALNY) and Ambrx Biopharma (AMAM).

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/22/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Business Services
• Current Symbol: NASDAQ:BIAF
• CIK: 1712762
• Web: www.bioaffinitytech.com
• Phone: 210-698-5334
• Fax: N/A
• Employees: 10
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): ($0.70)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$9.04 million
• Net Margins: -152.16%
• Pretax Margin: -151.64%
• Return on Equity: -845.68%
• Return on Assets: -181.92%

Debt

• Debt-to-Equity Ratio: 0.27
• Current Ratio: 0.64
• Quick Ratio: 0.53

Sales & Book Value

• Annual Sales: $9.36 million
• Price / Sales: 0.77
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($0.08) per share
• Price / Book: -3.17

Miscellaneous

• Outstanding Shares: 28,470,000
• Free Float: 23,649,000
• Market Cap: $7.22 million
• Optionable: Not Optionable
• Beta: 2.53